InvestorsObserver
×
News Home

Is Catalent Inc (CTLT) a Stock to Watch After Gaining 3.47% This Week?

Tuesday, October 19, 2021 02:46 PM | InvestorsObserver Analysts

Mentioned in this article

Is Catalent Inc (CTLT) a Stock to Watch After Gaining 3.47% This Week?

Catalent Inc (CTLT) stock has risen 3.47% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
Catalent Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CTLT!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CTLT Stock Today?

Catalent Inc (CTLT) stock is trading at $133.09 as of 2:37 PM on Tuesday, Oct 19, an increase of $2.64, or 2.02% from the previous closing price of $130.45. The stock has traded between $131.17 and $133.94 so far today. Volume today is below average. So far 315,055 shares have traded compared to average volume of 944,326 shares.

More About Catalent Inc

Catalent Inc is a specialty and generic drug manufacturing company. The company focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent's sales are generated in the United States, followed by Europe and the rest of the world. Most of the company's sales are derived from branded drug products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. It operates in four operating segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. Click Here to get the full Stock Report for Catalent Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App